Recro Pharma timeline
- 2014
- 🔔· approximateInitial public offering on Nasdaq
Events of Recro Pharma from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Recro Pharma
- Acquisitions and changes
- No longer listed: ticker REPH is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #2,545 (Jan 2020) · #3,896 (Jan 2021) · #4,629 (Jan 2022)
Lobbying by Recro Pharma#
$60 K spent on lobbying the US Congress and federal agencies in 2021, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2021
BGR Government Affairs $60 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2021 | $60 K | — | 1 |
| 2020 | $240 K | — | 4 |
| 2019 | $240 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Recro Pharma, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Recro Pharma#
5 labor condition applications certified in fiscal 2021 for 5 positions, at a median wage of $89 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Scientist II, Analytical DevelopmentChemists | 3 | $90 K |
| Scientist II, Product DevelopmentMedical Scientists, Except Epidemiologists | 1 | $89 K |
| Scientist III, Analytical DevelopmentChemists | 1 | $87 K |
Where: Gainesville, GA 5
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Recro Pharma, Inc.
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Recro Pharma🇺🇸 | $75 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 7, 2022 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Recro Pharma? Verify and update this profile — free
Show Recro Pharma's ranking on your website Get the badge
The badge updates itself as the ranking changes.